PureTech Health plc, after the multibillion-dollar success of its last neuropsychiatry venture Karuna Therapeutics Inc., launched Seaport Therapeutics in April with $100m in series A funding and on 21 October revealed that the start-up raised a $225m series B round to support clinical trials for its lead programs in depression and anxiety.
Finance Watch: PureTech’s Seaport Raises $225m For Depression, Anxiety Trials
Forbion’s Two New Funds Total €2bn ($2.2bn)
Private Company Edition: Seaport completed its series B round six months after launching with $100m. Also, Treeline disclosed $421.8m in new funding, among other recent $100m-plus VC mega-rounds, and three venture firms revealed more than $2.5bn in new funds.
